InMed Historical Balance Sheet

INM Stock

USD 4.95 0.45 10.00%

Trend analysis of InMed Pharmaceuticals balance sheet accounts such as Total Stockholder Equity of 11.1 M or Property Plant And Equipment Net of 1.5 M provides information on InMed Pharmaceuticals' total assets, liabilities, and equity, which is the actual value of InMed Pharmaceuticals to its prevalent stockholders. By breaking down trends over time using InMed Pharmaceuticals balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining InMed Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether InMed Pharmaceuticals is a good buy for the upcoming year.

InMed Pharmaceuticals Inventory

1.18 Million

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in InMed Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

To learn how to invest in InMed Stock, please use our How to Invest in InMed Pharmaceuticals guide.

About InMed Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of InMed Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. InMed Pharmaceuticals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of InMed Pharmaceuticals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which InMed currently owns. An asset can also be divided into two categories, current and non-current.

InMed Pharmaceuticals Balance Sheet Chart

At this time, InMed Pharmaceuticals' Non Currrent Assets Other are very stable compared to the past year. As of the 18th of January 2025, Net Receivables is likely to grow to about 333.4 K, though Retained Earnings are likely to grow to (93.3 M).

Total Assets Total Current Liabilities Property Plant And Equipment Net Accounts Payable Total Liab

Total Assets

Total assets refers to the total amount of InMed Pharmaceuticals assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in InMed Pharmaceuticals books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on InMed Pharmaceuticals balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of InMed Pharmaceuticals are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Property Plant And Equipment Net

The total value of a company's physical assets (such as land, buildings, and equipment) used in operations, net of depreciation. It reflects the company's investment in assets used for production.

Accounts Payable

An accounting item on the balance sheet that represents InMed Pharmaceuticals obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of InMed Pharmaceuticals are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Total Liab

The total amount of all liabilities that a company has, including both short-term and long-term liabilities.

Most accounts from InMed Pharmaceuticals' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into InMed Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in InMed Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

To learn how to invest in InMed Stock, please use our How to Invest in InMed Pharmaceuticals guide.At this time, InMed Pharmaceuticals' Non Currrent Assets Other are very stable compared to the past year. As of the 18th of January 2025, Net Receivables is likely to grow to about 333.4 K, though Retained Earnings are likely to grow to (93.3 M).

	2022	2023	2024	2025 (projected)
Total Current Liabilities	2.0M	2.0M	2.3M	2.4M
Total Assets	14.1M	11.8M	13.6M	14.3M

Total Current Liabilities Total Assets

InMed Pharmaceuticals balance sheet Correlations

	Total Assets	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Intangible Assets	Short Long Term Debt Total	Other Current Liab	Current Deferred Revenue	Short Term Debt	Good Will
Total Assets		0.66	0.99	0.29	-0.9	-0.62	0.76	0.95	0.4	-0.12	0.9	0.48	0.43	0.45	0.69	-0.05	-0.23	-0.17	0.64	0.99	0.29	0.44	0.52	-0.28	0.52	0.09
Total Current Liabilities	0.66		0.52	0.49	-0.37	-0.89	0.77	0.48	0.72	-0.12	0.36	0.57	0.54	0.52	0.36	-0.25	-0.2	0.29	0.99	0.56	0.57	0.67	0.84	-0.61	0.81	0.1
Total Stockholder Equity	0.99	0.52		0.2	-0.94	-0.5	0.69	0.97	0.28	-0.11	0.94	0.4	0.34	0.38	0.69	-0.01	-0.23	-0.27	0.5	0.99	0.2	0.33	0.41	-0.21	0.4	0.08
Property Plant And Equipment Net	0.29	0.49	0.2		0.07	-0.39	0.31	0.04	0.79	0.69	-0.01	0.75	0.6	0.56	0.37	0.09	-0.06	0.43	0.54	0.15	0.1	0.47	0.22	-0.06	0.57	-0.66
Net Debt	-0.9	-0.37	-0.94	0.07		0.36	-0.62	-0.98	0.01	0.25	-0.98	-0.12	-0.09	-0.15	-0.52	0.13	0.21	0.43	-0.33	-0.95	-0.06	-0.1	-0.35	0.23	-0.17	-0.23
Retained Earnings	-0.62	-0.89	-0.5	-0.39	0.36		-0.54	-0.47	-0.77	0.33	-0.32	-0.73	-0.73	-0.76	-0.29	0.15	0.36	-0.43	-0.91	-0.53	-0.77	-0.79	-0.71	0.5	-0.89	-0.31
Accounts Payable	0.76	0.77	0.69	0.31	-0.62	-0.54		0.66	0.29	0.0	0.68	0.26	0.19	0.14	0.66	-0.17	-0.01	-0.29	0.73	0.74	0.09	0.3	0.86	-0.38	0.39	0.03
Cash	0.95	0.48	0.97	0.04	-0.98	-0.47	0.66		0.15	-0.26	0.96	0.27	0.26	0.29	0.59	-0.11	-0.19	-0.34	0.45	0.98	0.18	0.27	0.39	-0.22	0.3	0.22
Non Current Assets Total	0.4	0.72	0.28	0.79	0.01	-0.77	0.29	0.15		0.16	-0.01	0.87	0.83	0.82	0.28	0.14	-0.22	0.67	0.78	0.25	0.69	0.84	0.36	-0.26	0.93	-0.19
Non Currrent Assets Other	-0.12	-0.12	-0.11	0.69	0.25	0.33	0.0	-0.26	0.16		-0.15	0.14	-0.1	-0.09	0.1	0.08	0.05	0.09	-0.13	-0.17	-0.56	-0.27	-0.21	0.09	-0.11	-0.91
Cash And Short Term Investments	0.9	0.36	0.94	-0.01	-0.98	-0.32	0.68	0.96	-0.01	-0.15		0.14	0.09	0.13	0.62	-0.09	-0.16	-0.47	0.31	0.95	-0.01	0.09	0.39	-0.18	0.14	0.19
Net Receivables	0.48	0.57	0.4	0.75	-0.12	-0.73	0.26	0.27	0.87	0.14	0.14		0.91	0.95	0.44	0.22	-0.31	0.49	0.65	0.35	0.53	0.78	0.29	-0.02	0.81	-0.17
Common Stock Shares Outstanding	0.43	0.54	0.34	0.6	-0.09	-0.73	0.19	0.26	0.83	-0.1	0.09	0.91		0.93	0.45	0.13	-0.05	0.47	0.65	0.31	0.65	0.91	0.25	0.11	0.76	0.02
Short Term Investments	0.45	0.52	0.38	0.56	-0.15	-0.76	0.14	0.29	0.82	-0.09	0.13	0.95	0.93		0.32	0.17	-0.41	0.51	0.6	0.34	0.67	0.79	0.25	-0.04	0.8	0.03
Non Current Liabilities Total	0.69	0.36	0.69	0.37	-0.52	-0.29	0.66	0.59	0.28	0.1	0.62	0.44	0.45	0.32		0.15	0.28	-0.29	0.4	0.68	0.02	0.43	0.37	0.26	0.25	-0.14
Inventory	-0.05	-0.25	-0.01	0.09	0.13	0.15	-0.17	-0.11	0.14	0.08	-0.09	0.22	0.13	0.17	0.15		-0.07	-0.13	-0.21	-0.07	0.12	0.17	-0.27	0.54	0.16	-0.07
Other Current Assets	-0.23	-0.2	-0.23	-0.06	0.21	0.36	-0.01	-0.19	-0.22	0.05	-0.16	-0.31	-0.05	-0.41	0.28	-0.07		-0.25	-0.13	-0.2	-0.29	0.07	-0.16	0.54	-0.39	-0.07
Other Stockholder Equity	-0.17	0.29	-0.27	0.43	0.43	-0.43	-0.29	-0.34	0.67	0.09	-0.47	0.49	0.47	0.51	-0.29	-0.13	-0.25		0.33	-0.29	0.58	0.47	-0.06	-0.37	0.6	-0.09
Total Liab	0.64	0.99	0.5	0.54	-0.33	-0.91	0.73	0.45	0.78	-0.13	0.31	0.65	0.65	0.6	0.4	-0.21	-0.13	0.33		0.53	0.62	0.77	0.8	-0.51	0.84	0.1
Total Current Assets	0.99	0.56	0.99	0.15	-0.95	-0.53	0.74	0.98	0.25	-0.17	0.95	0.35	0.31	0.34	0.68	-0.07	-0.2	-0.29	0.53		0.21	0.33	0.48	-0.25	0.39	0.14
Intangible Assets	0.29	0.57	0.2	0.1	-0.06	-0.77	0.09	0.18	0.69	-0.56	-0.01	0.53	0.65	0.67	0.02	0.12	-0.29	0.58	0.62	0.21		0.81	0.31	-0.32	0.83	0.48
Short Long Term Debt Total	0.44	0.67	0.33	0.47	-0.1	-0.79	0.3	0.27	0.84	-0.27	0.09	0.78	0.91	0.79	0.43	0.17	0.07	0.47	0.77	0.33	0.81		0.37	-0.02	0.84	0.19
Other Current Liab	0.52	0.84	0.41	0.22	-0.35	-0.71	0.86	0.39	0.36	-0.21	0.39	0.29	0.25	0.25	0.37	-0.27	-0.16	-0.06	0.8	0.48	0.31	0.37		-0.53	0.49	0.27
Current Deferred Revenue	-0.28	-0.61	-0.21	-0.06	0.23	0.5	-0.38	-0.22	-0.26	0.09	-0.18	-0.02	0.11	-0.04	0.26	0.54	0.54	-0.37	-0.51	-0.25	-0.32	-0.02	-0.53		-0.42	-0.14
Short Term Debt	0.52	0.81	0.4	0.57	-0.17	-0.89	0.39	0.3	0.93	-0.11	0.14	0.81	0.76	0.8	0.25	0.16	-0.39	0.6	0.84	0.39	0.83	0.84	0.49	-0.42		0.08
Good Will	0.09	0.1	0.08	-0.66	-0.23	-0.31	0.03	0.22	-0.19	-0.91	0.19	-0.17	0.02	0.03	-0.14	-0.07	-0.07	-0.09	0.1	0.14	0.48	0.19	0.27	-0.14	0.08

Click cells to compare fundamentals

InMed Pharmaceuticals Account Relationship Matchups

InMed Pharmaceuticals balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	9.8M	12.8M	14.1M	11.8M	13.6M	14.3M
Total Current Liabilities	2.2M	3.3M	2.0M	2.0M	2.3M	2.4M
Total Stockholder Equity	7.4M	9.1M	12.1M	9.2M	10.6M	11.1M
Property Plant And Equipment Net	326.6K	904.3K	723.4K	1.2M	1.4M	1.5M
Net Debt	(7.1M)	(5.4M)	(8.5M)	(5.6M)	(5.0M)	(4.8M)
Retained Earnings	(74.9M)	(93.5M)	(101.4M)	(109.1M)	(98.2M)	(93.3M)
Accounts Payable	775.1K	1.2M	544.2K	626.2K	720.1K	615.9K
Cash	7.4M	6.2M	8.9M	6.6M	7.6M	7.9M
Non Current Assets Total	1.4M	3.2M	2.8M	3.1M	3.6M	3.8M
Non Currrent Assets Other	14.7K	176.6K	104.9K	100K	90K	166.4K
Cash And Short Term Investments	7.4M	6.2M	8.9M	6.6M	7.6M	3.9M
Net Receivables	11.9K	88.0K	260.4K	352.8K	317.6K	333.4K
Common Stock Shares Outstanding	270K	560.8K	2.4M	7.6M	8.7M	9.2M
Short Term Investments	46.5K	44.8K	44.4M	43.1M	49.5M	52.0M
Liabilities And Stockholders Equity	9.8M	12.8M	14.1M	11.8M	13.6M	14.3M
Non Current Liabilities Total	189.3K	389.5K	16.0K	644.9K	741.6K	778.7K
Inventory	(955.8M)	2.5M	1.6M	1.2M	1.1M	1.2M
Other Current Assets	956.8K	842.0K	(8.9B)	477.7K	430.0K	451.5K
Other Stockholder Equity	21.5M	31.7M	35.7M	35.4M	31.8M	33.4M
Total Liab	2.4M	3.7M	2.0M	2.6M	3.0M	3.2M
Total Current Assets	8.4M	9.6M	11.3M	8.7M	10.0M	10.5M
Intangible Assets	1.1M	2.1M	1.9M	1.8M	2.1M	2.2M
Short Long Term Debt Total	269.8K	793.8K	391.7K	962.7K	1.1M	1.2M
Other Current Liab	1.4M	1.7M	1.1M	1.0M	1.2M	612.0K
Short Term Debt	80.5K	404.3K	375.7K	317.8K	365.5K	383.7K
Common Stock	60.6M	70.7M	77.6M	82.8M	95.2M	53.5M
Net Tangible Assets	6.5M	6.3M	7.0M	10.1M	9.1M	9.1M
Net Invested Capital	7.4M	9.1M	12.1M	9.2M	8.3M	8.4M
Net Working Capital	6.2M	6.3M	9.3M	6.7M	6.0M	7.1M
Property Plant Equipment	549.9K	326.6K	904.3K	723.4K	831.9K	873.5K
Capital Stock	60.6M	70.7M	77.6M	82.8M	95.2M	72.3M
Capital Lease Obligations	269.8K	793.8K	391.7K	962.7K	1.1M	627.0K
Property Plant And Equipment Gross	326.6K	1.4M	1.6M	2.6M	3.0M	3.1M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether InMed Pharmaceuticals is a strong investment it is important to analyze InMed Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact InMed Pharmaceuticals' future performance. For an informed investment choice regarding InMed Stock, refer to the following important reports:

How To Invest In InMed

Details

Is InMed Stock a good investment?

Details

What is InMed Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

To learn how to invest in InMed Stock, please use our How to Invest in InMed Pharmaceuticals guide.

You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of InMed Pharmaceuticals. If investors know InMed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about InMed Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

253.44

Revenue Per Share

0.603

Quarterly Revenue Growth

(0.45)

Return On Assets

(0.39)

Return On Equity

(0.72)

The market value of InMed Pharmaceuticals is measured differently than its book value, which is the value of InMed that is recorded on the company's balance sheet. Investors also form their own opinion of InMed Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is InMed Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because InMed Pharmaceuticals' market value can be influenced by many factors that don't directly affect InMed Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between InMed Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if InMed Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, InMed Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

InMed Historical Balance Sheet

InMed Pharmaceuticals Inventory

1.18 Million

About InMed Balance Sheet Analysis

InMed Pharmaceuticals Balance Sheet Chart

Total Assets

Total Current Liabilities

Property Plant And Equipment Net

Accounts Payable

Total Liab

InMed Pharmaceuticals balance sheet Correlations

InMed Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

InMed Pharmaceuticals balance sheet Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 0.99	Total Assets
Total Current Assets	+ 0.99	Total Assets
Total Liab	+ 0.99	Total Current Liabilities
Total Current Assets	+ 0.99	Total Stockholder Equity
Total Current Assets	+ 0.98	Cash
Cash	+ 0.97	Total Stockholder Equity

Cash And Short Term Investments	- 0.98	Net Debt
Cash	- 0.98	Net Debt
Total Current Assets	- 0.95	Net Debt
Net Debt	- 0.94	Total Stockholder Equity
Good Will	- 0.91	Non Currrent Assets Other
Total Liab	- 0.91	Retained Earnings